| answer text |
<p>There are currently no plans to review the licensing or availability of co-proxamol.</p><p>Co-proxamol
is a combination of paracetamol and dextropropoxyphene which was licensed for the
treatment of pain.</p><p>In 2004, the safety of co-proxamol was reviewed and it was
concluded that the benefits of co-proxamol did not outweigh the risks of accidental
overdose and death and that co-proxamol should be withdrawn from the market. All licences
in the United Kingdom were cancelled by the end of 2007.</p><p>This was communicated
to healthcare professionals in January 2005 with reminders in 2007 and 2011. Where
possible existing patients were to be switched to alternative pain medication and
no new patients should have been prescribed co-proxamol. It remains the case that
co-proxamol is an item that should not be routinely dispensed in primary care following
NHS England guidance.</p><p>As an unlicensed medicine, co-proxamol can be prescribed
on a named patient basis if it is judged to be the most appropriate treatment by the
prescribing doctor.</p><p> </p>
|
|
